Infutraze

Zinc chloride, potassium iodide, sodium selenite, copper chloride dihydrate and manganese chloride tetrahydrate, the active ingredients in Infutraze, are trace element supplements presented as an intravenous solution for parenteral use. They address trace element deficiencies in patients receiving total parenteral nutrition, particularly critically ill, postoperative or long‑term catheterized individuals who cannot obtain adequate micronutrients orally.

GNH USA supplies Infutraze as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive care units worldwide. The company adheres to EU quality standards and provides regulatory documentation for import.

Infutraze is used to correct trace element deficiencies and support metabolic processes in patients receiving parenteral nutrition.

Trace element deficiency: supplementation of essential minerals to restore normal biochemical function. Parenteral nutrition support: provides necessary trace elements to complete total nutrient formulations for patients unable to eat orally. Critical illness micronutrient prevention: helps prevent deficiency‑related complications in intensive care or postoperative patients. Renal replacement therapy: replaces trace elements removed during dialysis to maintain adequate levels.

Infutraze may be associated with adverse reactions related to its trace element composition and intravenous administration.

Common Side Effects: - Infusion site erythema or pain - Mild nausea or vomiting - Transient headache - Metallic taste - Elevated serum copper without clinical symptoms

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reaction - Copper toxicity manifesting as hepatic dysfunction - Selenium overdose causing respiratory distress - Manganese accumulation leading to neurotoxicity - Severe electrolyte imbalance (e.g., hypermagnesemia)

When using Infutraze, clinicians should observe specific safety measures. - Baseline assessment: measure serum zinc, copper and selenium levels before initiating therapy. - Monitoring: regularly check trace element concentrations during treatment. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Organ dysfunction: use with caution in hepatic or renal impairment, adjusting dose as needed. - Drug compatibility: verify compatibility with other IV solutions before co‑administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Infutraze can interact with other medications or supplements; awareness of these interactions helps maintain safety.

Major Interactions (Avoid): - Concurrent high‑dose copper supplements: risk of copper overload. - Concurrent high‑dose selenium preparations: risk of selenosis.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., heparin): trace elements may alter coagulation parameters. - Thyroid hormone therapy: iodine content may affect hormone levels. - Renal replacement therapy: dialysis may remove administered trace elements, requiring dose adjustment. - Aminoglycoside antibiotics: copper may influence nephrotoxicity risk.